FibroGen Receives Approval from China's Market Regulation Authority for Sale of FibroGen China to AstraZeneca

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Aug 18 2025

0mins

Source: Newsfilter

Sale Approval: The China State Administration for Market Regulation has approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, as per a Share Purchase Agreement dated February 20, 2025.
Closing Timeline: The transaction is expected to close in the third quarter of 2025, pending other contractual closing conditions and deliverables.
Company Overview: FibroGen, Inc. focuses on developing novel therapies for cancer biology and anemia, with its product Roxadustat already approved in multiple countries for treating anemia in chronic kidney disease patients.
Forward-Looking Statements: The release includes forward-looking statements regarding FibroGen's future plans and clinical programs, cautioning investors about potential risks and uncertainties that may affect actual results.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free